
Meditransfer Centrum Transferu Technologii Iitd sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
The Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences conducts research in clinical immunology, experimental cancer therapy, glycoimmunology, infection immunology and immunopharmacology. It also works on bacteriophages and phage therapy, molecular microbiology, virology, molecular biology, biochemistry and biotechnology. The institute can award doctoral and habilitation degrees in biological and medical sciences.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Brak okoliczności wskazujących na zagrożenie kontynuowania działalności.
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 273 days for 2020).
- 202501/09/2026
- 202414/07/2025
- 202313/07/2024
- 202221/02/2023
- 202118/10/2022
- 202015/07/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Industry
Websites
- hirszfeld.plInstytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii NaukWordPressYoast SEOPPolylangApache
Public procurement
2 tenders recorded as contractor, with a total value of $381,710.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Feb 24, 2026 | Provision of a system for a genetic laboratory together with analytical tools | $216K$215,964 | Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu | |
| Jul 15, 2025 | Service for managing innovation development and commercialisation processes | $165.7K$165,746 | Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu |
Authorized Representatives
Manner of representation
If the management board is multi-member, each member of the management board is authorised independently to make declarations of will on behalf of the company.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Instytut Immunologii i Terapi Doświadczalnej Im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu | 572 | $77,255.54 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-04-01.
75 1020 2241 0000 2502 0074 9374
85 1020 2241 0000 2202 0078 0866
03 1020 5226 0000 6802 0770 1917
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 23, 2023 | Aid for research and development projects: experimental development | –– | Prezes Agencji Badań Medycznych | |
| Oct 23, 2023 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biotts S.A. | $159,262.71 | biotts.com | ||
| Cofactor sp. z o.o. | $136,474.66 | cofactor.pl | ||
| Technology Transfer Agency Techtra sp. z o.o. | $101,811.99 | techtra.pl | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Target Cells sp. z o.o. | $41,315.36 | targetcells.pl | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| HPV Diagnostics sp. z o.o. | $36,528.47 | hpvdiagnostics.com | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Cellis sp. z o.o. | $24,935.59 | cellis.eu | ||
| Thesybin Labs P.S.A. | $8,297.34 | thesybin.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-23 | Name change (Centrum Transferu Technologii Meditransfer Iitd → Meditransfer Centrum Transferu Technologii Iitd) | |
| 2026-09-23 | Share capital increase (276,000.00 PLN → 286,000.00 PLN) | |
| 2022-09-23 | Name change (Centrum Transferu Technologii Iitd → Centrum Transferu Technologii Meditransfer Iitd) | |
| 2022-09-23 | PKD change (Added: 72.11.Z, 72.19.Z, 82.30, 85.60.Z) | |
| 2018-09-05 | Share capital increase (274,000.00 PLN → 276,000.00 PLN) |
FAQ
Last updated: 2026-10-02


